# US 2013/0281394 A1 · Chemosensory Receptor Ligand-Based Therapies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0281394 A1
- Document ID: US20130281394A1
- Status: Published application
- Kind: A1
- Application number: 13/880,720
- Filed: 2011-10-18
- Published: 2013-10-24
- Earliest claimed: 2010-10-19
- Assignees: Elcelyx Therapeutics, Inc.
- Inventors: Alain D. Baron; Martin R. Brown; Christopher R.G. Jones; Nigel R.A. Beeley
- Web page: https://patentgrep.com/patent/US20130281394A1

## CPC

- C07C 309/46: having the sulfo groups bound to carbon atoms of non-condensed six-membered aromatic rings
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2086: {Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat (active cores with a complete drug-free outer coat A61K9/28)}
- A61K 9/2846: {Poly(meth)acrylates}
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 31/166: having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/197: the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K31/205)
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/201: having one or two double bonds, e.g. oleic, linoleic acids
- A61K 31/216: of acids having aromatic rings, e.g. benactizyne, clofibrate
- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K 31/36: Compounds containing methylenedioxyphenyl groups, e.g. sesamin
- A61K 31/405: Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/7016: Disaccharides, e.g. lactose, lactulose (lactobionic acid A61K31/7032)
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 38/05: Dipeptides
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/10: Laxatives
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/12: Antidiuretics, e.g. drugs for diabetes insipidus (ADH A61P5/10)
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- C07C 69/28: esterified with dihydroxylic compounds
- C07C 69/533: Monocarboxylic acid esters having only one carbon-to-carbon double bond
- C07C 233/75: with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C 235/64: having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C 237/08: having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07D 209/20: substituted additionally by nitrogen atoms, e.g. tryptophane
- C07D 307/85: attached in position 2
- C07D 317/68: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory receptor ligand. Also provided herein are chemosensory receptor ligand compositions and methods for the preparation thereof for use in the methods of the present invention.

## Claims

### Claim 1

A composition comprising a chemosensory receptor ligand selected from the following structures:
wherein the composition is adapted to release a therapeutically effective amount of the ligand to one or more regions of the intestine of a subject.

### Claim 2

A composition comprising a chemosensory receptor ligand selected from a compound of structural Formula I,
wherein
Aa is an amino acid residue bonded to the adjacent carbonyl group via the N-alpha nitrogen and is selected from the group consisting of,
alanine (Ala), isoleucine (Ile), leucine (Leu), methionine (Met), tert-leucine (t-Leu), and valine (Val); and
n is an integer between 8 and 22; and
wherein the composition is adapted to release a therapeutically effective amount of the ligand to one or more regions of the intestine of a subject.

### Claim 3

A composition comprising a chemosensory receptor ligand selected from a di- or tripeptide compound of structural Formula II,
wherein
Aa1 is an amino acid residue bonded to the adjacent carbonyl group via the N-alpha nitrogen and is selected from the group consisting of,
aminobutyric acid (Abu), alanine (Ala), aspartic acid (Asp), cysteine (Cys), S-methyl cysteine (Cys(SMe)), S-methyl cysteine sulfoxide (Cys(SMe)(O)), S-allyl cysteine (Cys(S-allyl), S-nitroso cysteine (Cys(SNO)), glutamic acid (Glu), γ-glutamic acid (γ-Glu), glycine (Gly), isoleucine (Ile), leucine (Leu), methionine (Met), methionine-5-sulfoxide (Met(O)), ornithine (Orn), serine (Ser), taurine (Tau), threonine (Thr), tert-leucine (t-Leu), valine (Val), valinamide (Val-NH2), and valinol (Val-ol); and
Aa2 is either absent or is an amino acid residue bonded to the adjacent carbonyl group via the N-alpha nitrogen selected from a group consisting of,
arginine (Arg), aspartic acid (Asp), asparagine (Asn), cysteine (Cys), glutamic acid (Glu), glutamine (Gln), glycine (Gly), lysine (Lys), methionine (Met), ornithine (Orn), phenylalanine (Phe), proline (Pro), serine (Ser), and valine (Val); and
wherein the composition is adapted to release a therapeutically effective amount of the ligand to one or more regions of the intestine of a subject.

### Claim 4 (depends on 3)

A composition according to claim 3, wherein the di- or tripeptide compound of Formula II is selected from the following: γ-Glu-Met(O), γ-Glu-Val-Val, γ-Glu-Val-Glu, γ-Glu-Val-Lys, γ-Glu-Val-Arg, γ-Glu-Val-Asp, γ-Glu-Val-Met, γ-Glu-Val-Thr, γ-Glu-γ-Glu-Val, γ-Glu-Val-NH2, γ-Glu-Val-ol, γ-Glu-Ser, γ-Glu-Tau, γ-Glu-Cys(SMe)(O), γ-Glu-Val-His, γ-Glu-Val-Orn, γ-Glu-Leu, γ-Glu-Ile, γ-Glu-t-Leu, γ-Glu-Cys(S-allyl)-Gly, γ-Glu-Val-Asn, γ-Glu-Gly-Gly, γ-Glu-Val-Phe, γ-Glu-Val-Ser, γ-Glu-Val-Pro, γ-Glu-Ser-Gly, γ-Glu-Cys(SMe), γ-Glu-Cys(SNO), γ-Glu-Val-Cys, γ-Glu-Val-Gln, γ-Glu-Abu-Gly, γ-Glu-Cys(SMe)-Gly, γ-Glu-Val-Gly, γ-Glu-Cys(SNO)-Gly, γ-Glu-Cys-Gly, γ-Glu-Cys, γ-Glu-Met, γ-Glu-Thr, γ-Glu-Val, γ-Glu-Orn, γ-Glu-Gly and γ-Glu-Ala.

### Claim 5

A composition comprising a chemosensory receptor ligand that is a dipeptide compound selected from the following: Asp-Gly, Cys-Gly, Cys-Met, Glu-Cys, Gly-Cys, Leu-Asp and Asp-Cys; and
wherein the composition is adapted to release a therapeutically effective amount of the ligand to one or more regions of the intestine of a subject.

### Claim 6

A composition comprising a chemosensory receptor ligand having the formula γ-Glu-X-Gly, wherein X is selected from: Ala, Leu, Ile, Thr, Met, Asn, Gln, Pro, hydroxproline, Asp, Glu, Lys, Arg, His, Phe, Tyr, Trp, homoserine, citrulline, Orn, norvaline, norleucine, and Tau; and wherein the composition is adapted to release a therapeutically effective amount of the ligand to one or more regions of the intestine of a subject.

### Claim 7

A composition comprising a chemosensory receptor ligand comprising poly-γ-glutamic acid having a weight-average molecular weight of equal to or greater than 3×103; and wherein the composition is adapted to release a therapeutically effective amount of the ligand to one or more regions of the intestine of a subject.

### Claim 8

A composition comprising a chemosensory receptor ligand selected from a compound of structural Formula III,
wherein
R1 and R2 are each independently selected from:
C1-C10 substituted or unsubstituted straight chain or branched chain alkyl, substituted or unsubstituted C4-C10 alkylcycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heteroaryl and substituted or unsubstituted alkyl heteroaryl; and
wherein the composition is adapted to release a therapeutically effective amount of the ligand to one or more regions of the intestine of a subject.

### Claim 9

(canceled)

### Claim 10 (depends on 8)

A composition according to claim 8, wherein the compound of Formula III is selected from the following structures,

### Claim 11 (depends on 8)

A composition according to claim 8, wherein the compound of Formula III is selected from the following structures,

### Claim 12

A composition comprising a chemosensory receptor ligand selected from the following structures:
wherein the composition is adapted to release a therapeutically effective amount of the ligand to one or more regions of the intestine of a subject.

### Claim 13

A composition comprising a chemosensory receptor ligand selected from a compound of structural Formula IV,
wherein
R1 and R3 are each independently selected from:
H, OH, F, Cl, Br, I, C1-C6 straight chain or branched chain alkyl, O—(C1-C6 straight chain or branched chain alkyl), O—(C3-C7 cycloalkyl), O—(C4-C8 alkylcycloalkyl) and SO3H;
R2 is independently selected from:
H, SO3H, CO2H, PO3H2, PO2(OCH3)H and NO2;
R4 is independently selected from:
H, OH, F, Cl, Br, I and NO2,
R5 is independently selected from:
H, F, Cl, Br, I and C1-C6 straight chain or branched chain alkyl; and
with the proviso that at least two of R1, R2, R3, R4 and R5 are H;
R6 is selected from:
H, OH and C1-C6 straight chain or branched chain alkyl; and
X is selected from:
CH2 and O; and
wherein the composition is adapted to release a therapeutically effective amount of the ligand to one or more regions of the intestine of a subject.

### Claim 14 (depends on 13)

A composition according to claim 13, wherein the compound of Formula IV is selected from the following structures:

### Claim 15

A composition comprising a chemosensory receptor ligand selected from the following structures:
wherein n is an integer between 0 and 10; and
wherein the composition is adapted to release a therapeutically effective amount of the ligand to one or more regions of the intestine of a subject.

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18 (depends on 1)

A composition according to claim 1, wherein the composition further releases at least some of the chemosensory receptor ligand in the stomach.

### Claim 19 (depends on 1)

A composition according to claim 1, wherein one or more regions of the intestine are the duodenum, jejunum, ileum, caecum, colon and/or rectum.

### Claim 20

(canceled)

### Claim 21 (depends on 1)

A composition according to claim 1, wherein the composition releases at an onset of about 5 to about 45 minutes, about 105 to about 135 minutes, about 165 to about 195 minutes, about 225 to about 255 minutes or a combination of times thereof following administration to a subject.

### Claim 22 (depends on 1)

A composition according to claim 1, wherein the composition releases at an onset of about pH 5.0, about pH 5.5, about pH 6.0, about pH 6.5, about pH 7.0, or combination thereof following administration to a subject.

### Claim 23 (depends on 1)

A composition according to claim 1, the composition further comprising a second chemosensory receptor ligand that is selected from the group consisting of a sweet receptor ligand, a bitter receptor ligand, an umami receptor ligand, a fat receptor ligand, a sour receptor ligand and a bile acid receptor ligand.

### Claim 24 (depends on 31)

A composition according to claim 31, wherein said sweet receptor ligand is selected from the group consisting of sucralose, aspartame, Stevioside, Rebaudioside A, Rebaudioside B, Rebaudioside C, Rebaudioside D, Rebaudioside E, Rebaudioside F, Neotame, acesulfame-K, saccharin, and polymorphs thereof.

### Claim 25 (depends on 23)

A composition according to claim 23, wherein the bitter receptor ligand is selected from the group consisting of a flavanone, a flavone, a flavonol, a flavan, a phenolic flavonoid, an isoflavone, a limonoid aglycone, a glucosinolate or hydrolysis product thereof and an organic isothiocyanate.

### Claim 26 (depends on 23)

A composition according to claim 23, wherein the umami receptor ligand is selected from the group consisting of glutamate salt, glutamine, acetyl glycine and aspartame.

### Claim 27 (depends on 23)

A composition according to claim 23, wherein the fat receptor ligand is selected from the group consisting of a linoleic acid, an oleic acid, an omega-3 fatty acid, a palmitate, an oleoylethanolamide, a mixed fatty acid emulsion and an N-acylphosphatidylethanolamine (NAPE).

### Claim 28 (depends on 23)

A composition according to claim 23, wherein the sour receptor ligand is selected from the group consisting of citric acid and hydroxycitric acid.

### Claim 29 (depends on 23)

A composition according to claim 23, wherein the bile acid receptor ligand is selected from the group consisting of deoxycholic acid, a taurocholic acid and a chenodeoxycholic acid.

### Claim 30 (depends on 23)

A composition according to claim 23, the composition further comprising a chemosensory receptor enhancer selected from the group consisting of a sweet receptor enhancer, a bitter receptor enhancer, an umami receptor enhancer, a fat receptor enhancer, a sour receptor enhancer and a bile acid receptor enhancer.

### Claim 31

(canceled)

### Claim 32

(canceled)

### Claim 33

(canceled)

### Claim 34

(canceled)

### Claim 35

(canceled)

### Claim 36

(canceled)

### Claim 37

(canceled)

### Claim 38

(canceled)

### Claim 39

(canceled)

### Claim 40 (depends on 1)

A method of treating a condition associated with a chemosensory receptor in a subject comprising administering a composition according to claim 1.

### Claim 41

(canceled)

### Claim 42

(canceled)

### Claim 43

(canceled)

### Claim 44

(canceled)

### Claim 45

(canceled)

### Claim 46

(canceled)

### Claim 47

(canceled)

### Claim 48

(canceled)

### Claim 49

(canceled)

### Claim 50

(canceled)

### Claim 51

(canceled)

### Claim 52

(canceled)

### Claim 53

(canceled)

### Claim 54 (depends on 40)

A method according to claim 40, wherein the condition associated with a chemosensory receptor is selected from metabolic syndrome, diabetes type I, diabetes type II, obesity, binge eating, undesired food cravings, food addiction, a desire to reduce food intake or to lose weight or maintain weight loss, desire to maintain healthy weight, desire to maintain normal blood glucose metabolism, anorexia, pre-diabetes, glucose intolerance, gestational diabetes mellitus (GDM), impaired fasting glycemia (IFG), post-prandial hyperglycemia, accelerated gastric emptying, dumping syndrome, delayed gastric emptying, dyslipidemia, post-prandial dyslipidemia, hyperlipidemia, hypertriglyceridemia, post-prandial hypertriglyceridemia, insulin resistance, bone loss disorders, osteopenia, osteoporosis, muscle wasting disease, muscle degenerative disorders, polycystic ovary syndrome (PCOS), non-alcoholic fatty liver disease (NAFL), non-alcoholic steatohepatitis (NASH), immune disorders of the gut, celiac disease, bowel irregularity, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), ulcerative colitis, Crohn's disease, short bowel syndrome, peripheral neuropathy and diabetic neuropathy.

### Claim 55

(canceled)

### Claim 56

(canceled)

### Claim 57

(canceled)

### Claim 58

(canceled)

### Claim 59 (depends on 1)

A method of treating a disease, disorder or defect in energy homeostasis in a subject comprising administering a composition according to claim 1.
